Wanbang Pharmaceutical Science and Technology Co., Ltd. (hereinafter referred to as WB Technology) is a core subsidiary of Wanbang Biopharmaceuticals (Group) (hereinafter referred to as Wanbang Biopharma). It’s jointly invested by Wanbang Biopharma and a scientists team, aiming to build a unicorn enterprise for the R&D of biotechnology drugs.

WB Technology focuses on the therapeutic area of unmet needs of endocrine, cardiovascular and anti-tumor, relying on the protein polypeptide drugs innovation platform, cultivating efficient expression platform and difficult preparation platform, based on the biosimilar products, combining generic and innovation drugs, actively explores cooperation innovation mechanism, and continues to market biomacromolecules with clinical advantages.

WB Technology now has 2 subsidiaries and more than 15 projects under research and is equipped with international advanced laboratory instruments as well as platform technology. Employees with master's degree or above account for more than 53%.